eTheRNA intends to build high-value strategic collaborations for exploring the benefits of the TriMix technology in various disease areas.
eTheRNA seeks collaborative partnerships with pharma companies that enable us to develop - and ultimately also to commercialize - differentiated TriMix-based immunotherapies on either a risk-sharing or out-licensing basis.
mRNA Production Partnering
eTheRNA operates a cGMP accredited mRNA production facility in Niel, Belgium and currently focusses on producing mRNA-constructs exclusively for its own development plans. However as the clinical development program advances, the Company has the option to expand capacity and explore strategic partnerships.